Drug Trial Radar · NCT01252810
Safety Study of GE-145 320 mg I/mL Injection vs. Iopamidol 370 mg I/mL in Elderly Subjects Undergoing Coronary Procedure
Last checked: Nov 19, 2026Latest source record: Aug 29, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
284
Actual
Start
Nov 2010
Primary completion
Dec 2012
Study completion Dec 2012
Sponsor
- Lead sponsor
- GE HealthcareIndustry
- Sponsor type
- Industry
- Collaborators
- i3 Statprobe; Medpace, Inc.; Biomedical Systems; Rules-Based Medicine, Inc.
- First posted
- Dec 3, 2010
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Diagnostic
- Who can join
- All sexes, from 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate cardio-renal and overall safety profile of GE 145 320 mg I/ml Injection when compared to iopamidol 370 mg I/mL. The study will focus on elderly subjects with either chronic renal insufficiency, or diabetes mellitus (DM) requiring drug therapy, or congestive heart failure (CHF) NYHA Class III or greater, who are referred for a coronary catheterization procedure with or without PCI.
Conditions
- Chronic Renal Insufficiency
- Diabete Mellitus
- Congestive Heart Failure
Interventions
GE-145Drug
GE-145-320 mg I/mL as a single iv. administration. Comparator agent Isovue (iopamidol) 370 mg I/mL as a single iv. administration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Comparison of Overall Image Quality Between Ioforminol and Iopamidol-enhanced Images as Determined by an Independent Reader.Time frame: After the imaging date for either Ioforminol or Iopamidol.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
GE Healthcare
Princeton, New Jersey
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.